Genmab — Marts 2018
-
Man må formode at BMS tror mere på dara end cv301, da BMS sponsorerer opdivo/dara medens opdivo/cv301 sponsoreres af tredie part.
-
God morgen.
-
God morgen
-
Vi landede i går på en top fra d. 26. februar. Den må vi da meget gerne sige farvel til med en stigning mod de 1.278 som kan udløse et golden cross.
-
Så må det vente til mandag.
-
Jeg har sjældent interesse for kursbevægelser på den korte bane. Finder det dog spændende og lærerigt, at observere i hvilket omfang teknisk analyse og den faktiske handel udspiller sig.
-
Another article on that patient from the Sirius trial Gentogen mentioned wednesday - http://www.multiplemyelomahub.com/medical-information/case-study-triple-refractory-mm-patient-with-sustained-response-to-daratumumab-monotherapy - Would be nice if that story could gain some attention in the media
-
Well E L, if everybody here publish it on their Facebook sites, then the first steps are done
-
there is a lot of these stories in the Daratumumab group on facebook, they update every day, It is a closed group, but they let you in easily
-
i have been following it for a long time, they all talk about how well Dara is tolerated, with very few sideeffects. Completely different story with rev, velcade, pom, dex etc
-
Thanks mobby. I just send a request to join
-
Seattle Genetics trying a new drug targeting CD48 - https://www.myelomacrowd.org/seattle-genetics-sgn-cd48a-for-patients-with-relapsed-refractory-mm/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind